Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
Andre van der WesthuizenMegan LyleMoira C GravesXiaoqiang ZhuJason Wing Hon WongKerrie CornallShu RenLeanna PuglieseRichard LevyAdeeb MajidRicardo E VilainNikola A BowdenPublished in: Cancer research communications (2022)
There are limited treatments for melanoma once resistance to ICB occurs. Chemotherapy induces immune-related responses and may be repurposed to reinstate the response to ICB. This study provides the first evidence that chemotherapy can provide clinical benefit and increase OS for ICB-resistant melanoma.